Please assess the completion status of the following clinical trial:

Trial Title: Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically proven HER-2 positive~* Newly diagnosed or recurrent (after surgery) stage IV disease (TNM/AJCC v.7).~* Patients must have measurable (RECIST v. 1.1) or evaluable disease~* Performance status (PS) 0-3 (WHO)~* Age ≥ 70 years of age, or ≥ 60 years old with required number of dependencies~* Life expectancy of more than 12 weeks~* Previous adjuvant chemotherapy/anti HER-2 therapy after surgery is allowed, given that the time interval from end of previous treatment to initiation of treatment for metastatic disease is ≥ 6 months.~* Up to one line of anti-HER therapy (trastuzumab or lapatinib) is allowed in combination with hormone therapy for hormone sensitive metastatic breast cancer.~* Adequate organ function~* Before patient randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.~Exclusion Criteria:~* No brain metastases that are untreated, symptomatic, or require steroids to control symptoms; or any radiation, surgery, or other therapy to control symptoms from brain metastases within 2 months prior to the first study treatment.~* No prior chemotherapy for metastatic disease is allowed~* No prior treatment with pertuzumab is allowed~* No history of exposure to the following cumulative doses of anthracyclines:~* Doxorubicin or liposomal doxorubicin \> 360 mg/m2~* Epirubicin \> 720 mg/m2~* Mitoxantrone \> 120 mg/m2~* Idarubicin \> 90 mg/m2~* If another anthracycline or more than 1 anthracycline has been used, then the cumulative dose must not exceed the equivalent of 360 mg/m2 of doxorubicin.~* No history of palliative radiotherapy within 14 days of randomization~* No history of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or basal cell or spinocellular carcinoma of the skin~* No current uncontrolled hypertension (persistent systolic \> 180 mmHg and/or diastolic \> 100 mmHg)~* No LVEF below 50%~* No history of significant cardiac disease defined as:~* Symptomatic CHF (NYHA classes II-IV)~* High-risk uncontrolled arrhythmias~* History of myocardial infarction within 6 months prior to randomization~* Clinically significant valvular heart disease~* No angina pectoris requiring anti-angina treatment~* No peripheral neuropathy of Grade ≥ 3 per NCI CTCAE version 4.0.~* No current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures, known infection with HIV, active hepatitis B and/or hepatitis C virus)~* No major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment~* No history of receiving any investigational treatment within 28 days of randomization~* No history of intolerance (including Grade 3-4 infusion reaction) to trastuzumab~* No unwillingness or inability to comply with the requirements of the protocol as assessed by the investigator~* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pertuzumab + trastuzumab (PH) (Type: ACTIVE_COMPARATOR): Pertuzumab + trastuzumab. After progression,patients will be given the option of receiving T-DM1
- PH + metronomic chemotherapy (PHM) (Type: EXPERIMENTAL): Pertuzumab + trastuzumab + metronomic chemotherapy. After progression,patients will be given the option of receiving T-DM1

Based on this trial design, predict the completion outcome and termination type (if applicable).